We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 3.25 | 26.53% | 15.50 | 15.00 | 16.00 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 17.35 | 14.50 | 14.75 | 12,615,904 | 15:48:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.86 | 40.39M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 24/4/2024 | 10:32 | ALNC |  Angle shares jump on supplier agreement with with AstraZeneca |
| 24/4/2024 | 07:00 | UK RNS | Angle PLC New commercial agreement with AstraZeneca |
| 22/4/2024 | 16:52 | ALNC | IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide |
| 22/4/2024 | 07:00 | UK RNS | Angle PLC US and EU patents for innovative CellKeep™ slide |
| 08/4/2024 | 07:00 | UK RNS | Angle PLC Parsortix HER2 assay showcased at AACR 2024 |
| 22/3/2024 | 07:00 | UK RNS | Angle PLC Parsortix at European breast cancer conference |
| 22/1/2024 | 18:03 | ALNC | IN BRIEF: Angle highlights supportive data for DNA analysis tool |
| 22/1/2024 | 07:00 | RNSNON | Angle PLC Potential utility in precision oncology |
| 10/1/2024 | 12:57 | UKREG | Angle PLC Standard form for notification of major holdings |
| 04/1/2024 | 12:19 | ALNC | Angle shares soar following "breakthrough" cancer diagnostics results |
1 Year Angle Chart |
Intraday Angle Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
